Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1

  • Authors:
    • Zhenqi Huang
    • Xinglin Liang
    • Wei Wu
    • Xiaowen Chen
    • Qingshu Zeng
    • Mingzhen Yang
    • Jian Ge
    • Ruixiang Xia
  • View Affiliations

  • Published online on: October 16, 2018     https://doi.org/10.3892/or.2018.6797
  • Pages: 415-426
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Snail family transcriptional repressor 1 gene (Snail1) was screened in multiple myeloma cells (MMCs) from bortezomib-resistant MM patients and was found to be significantly associated with the development of drug-resistance mechanisms. In the present study, we first confirmed that the protein expression of Snail1 in bortezomib-resistant MMCs was significantly higher than that in MMCs without bortezomib resistance. The mechanistic studies confirmed that the enhancement of Snail1 expression in bortezomib-resistant MMCs directly upregulated transcription of the intracellular MDR1 gene to immediately develop multiple drug resistance mechanisms and inhibited P53 protein expression through the Snail1/hsa-miRNA-22-3p/P53 pathway to inhibit tumor cell apoptosis. By upregulating MDR1 and downregulating P53, Snail1 induced the drug resistance of MMCs to bortezomib, while Snail1 gene silencing effectively improved the drug sensitivity of MMCs to bortezomib chemotherapy. The present study further elucidated the drug resistance mechanisms of MMCs and provides evidence for increased clinical efficacy of bortezomib in MM patients.

References

1 

Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, et al: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67:1783–1792. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M and Baz RC: A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 121:3622–3630. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Nikesitch N and Ling SC: Molecular mechanisms in multiple myeloma drug resistance. J Clin Pathol. 69:97–101. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI

5 

Chauhan D and Anderson KC: Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis. 8:337–343. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al: Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65:6282–6293. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, et al: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66:184–191. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Murray MY, Auger MJ and Bowles KM: Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans. 42:804–808. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al: NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Yu W, Chen Y, Xiang R, Xu W, Wang Y, Tong J, Zhang N, Wu Y and Yan H: Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leuk Lymphoma. 58:428–437. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Abe M: Multiple myeloma. Nihon Rinsho. 67:991–995. 2009.(In Japanese). PubMed/NCBI

12 

Tomono T, Yano K and Ogihara T: Snail-induced epithelial-to-mesenchymal transition enhances P-gp-mediated multidrug resistance in HCC827 cells. J Pharm Sci. 106:2642–2649. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Cho JH, Lee SJ, Oh AY, Yoon MH, Woo TG and Park BJ: NF2 blocks Snail-mediated p53 suppression in mesothelioma. Oncotarget. 6:10073–10085. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Abdi J, Chen G and Chang H: Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget. 4:2186–2207. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Gaultney JG, Ng TW, Uyl-de Groot CA, Sonneveld P, van Beers EH, van Vliet MH and Redekop WK: Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. Pharmacogenomics. 19:213–226. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Wu T, Zhou J, Wang C, Wang B, Zhang S and Bai H: Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report. Oncol Lett. 14:7318–7322. 2017.PubMed/NCBI

17 

Gavriatopoulou M, Terpos E, Kastritis E and Dimopoulos MA: Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 16:237–245. 2017.PubMed/NCBI

18 

Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L and Král Z: Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials. Vnitr Lek. 59:37–58. 2013.(In Czech).

19 

Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, et al: Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. J Chemother. 24:167–172. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Jacob P, Hirt H and Bendahmane A: The heat-shock protein/chaperone network and multiple stress resistance. Plant Biotechnol J. 15:405–414. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Carmichael CL and Haigh JJ: The Snail family in normal and malignant haematopoiesis. Cells Tissues Organs. 203:82–98. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW and Shen CY: Mechanisms of inactivation of E-cadherin in breast carcinoma: Modification of the two-hit hypothesis of tumor suppressor gene. Oncogene. 20:pp. 3814–3823. 2001, View Article : Google Scholar : PubMed/NCBI

24 

Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ, Young GD, et al: Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis. 28:593–614. 2011. View Article : Google Scholar : PubMed/NCBI

25 

Barnett P, Arnold RS, Mezencev R, Chung LW, Zayzafoon M and Odero-Marah V: Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochem Biophys Res Commun. 404:34–39. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH and Du J: Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol. 723:156–166. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Zhang K, Wang X and Wang H: Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line. Mol Med Rep. 10:2065–2072. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Kawashima A, Takayama H, Kawamura N, Doi N, Sato M, Hatano K, Nagahara A, Uemura M, Nakai Y, Nishimura K, et al: Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol Lett. 4:15–21. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Brozovic A: The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 91:605–619. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Semina SE, Scherbakov AM, Kovalev SV, Shevchenko VE and Krasil'nikov MA: Horizontal transfer of tamoxifen resistance in MCF-7 cell derivates: Proteome study. Cancer Invest. 35:506–518. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Foo WC, Garcia-Blanco MA, et al: Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget. 7:50507–50521. 2016. View Article : Google Scholar : PubMed/NCBI

32 

Zhan M, Yu D, Lang A, Li L and Pollock RE: Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer. 92:1556–1566. 2001. View Article : Google Scholar : PubMed/NCBI

33 

Hasna J, Hague F, Rodat-Despoix L, Geerts D, Leroy C, Tulasne D, Ouadid-Ahidouch H and Kischel P: Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: The p53 connection. Cell Death Differ. 25:691–705. 2018.PubMed/NCBI

34 

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT and Yaffe MB: A pleiotropic RNA-binding protein controls distinct cell cycle checkpoints to drive resistance of p53-defective tumors to chemotherapy. Cancer Cell. 28:8312015. View Article : Google Scholar : PubMed/NCBI

35 

Luanpitpong S, Angsutararux P, Samart P, Chanthra N, Chanvorachote P and Issaragrisil S: Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma. Sci Rep. 7:106072017. View Article : Google Scholar : PubMed/NCBI

36 

Singh MS, Tammam SN, Shetab Boushehri MA and Lamprecht A: MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res. 126:2–30. 2017. View Article : Google Scholar : PubMed/NCBI

37 

Montazami N, Aghapour M, Farajnia S and Baradaran B: New insights into the mechanisms of multidrug resistance in cancers. Cell Mol Biol (Noisy-le-grand). 61:70–80. 2015.PubMed/NCBI

38 

Mancuso MR and Massarweh SA: Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. Curr Probl Cancer. 40:95–105. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Bach DH, Hong JY, Park HJ and Lee SK: The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer. 141:220–230. 2017. View Article : Google Scholar : PubMed/NCBI

40 

Çalışkan M, Güler H and Bozok Çetintaş V: Current updates on microRNAs as regulators of chemoresistance. Biomed Pharmacother. 95:1000–1012. 2017. View Article : Google Scholar : PubMed/NCBI

41 

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, et al: MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J. 7:6542017. View Article : Google Scholar : PubMed/NCBI

42 

Fan W, Huang J, Xiao H and Liang Z: MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN. Mol Med Rep. 13:4800–4806. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Wang J, Li Y, Ding M, Zhang H, Xu X and Tang J: Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review). Int J Oncol. 50:345–355. 2017. View Article : Google Scholar : PubMed/NCBI

44 

JThottassery JV, Zambetti GP, Arimori K, Schuetz EG and Schuetz JD: p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 94:11037–11042. 1997. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2019
Volume 41 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Huang, Z., Liang, X., Wu, W., Chen, X., Zeng, Q., Yang, M. ... Xia, R. (2019). Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. Oncology Reports, 41, 415-426. https://doi.org/10.3892/or.2018.6797
MLA
Huang, Z., Liang, X., Wu, W., Chen, X., Zeng, Q., Yang, M., Ge, J., Xia, R."Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1". Oncology Reports 41.1 (2019): 415-426.
Chicago
Huang, Z., Liang, X., Wu, W., Chen, X., Zeng, Q., Yang, M., Ge, J., Xia, R."Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1". Oncology Reports 41, no. 1 (2019): 415-426. https://doi.org/10.3892/or.2018.6797